Literature DB >> 1302032

Fragile X syndrome without CCG amplification has an FMR1 deletion.

A K Gedeon1, E Baker, H Robinson, M W Partington, B Gross, A Manca, B Korn, A Poustka, S Yu, G R Sutherland.   

Abstract

We describe a patient with typical clinical features of the fragile X syndrome, but without cytogenetic expression of the fragile X or an amplified CCG trinucleotide repeat fragment. The patient has a previously uncharacterized submicroscopic deletion encompassing the CCG repeat, the entire FMR1 gene and about 2.5 megabases of flanking sequences. This finding confirms that the fragile X phenotype can exist, without amplification of the CCG repeat or cytogenetic expression of the fragile X, and that fragile X syndrome is a genetically homogeneous disorder involving FMR1. We also found random X-inactivation in the mother of the patient who was shown to be a carrier of this deletion.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1302032     DOI: 10.1038/ng0892-341

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  56 in total

Review 1.  Epigenetic changes and non-coding expanded repeats.

Authors:  Masayuki Nakamori; Charles Thornton
Journal:  Neurobiol Dis       Date:  2010-02-18       Impact factor: 5.996

Review 2.  Mutation spectra in fragile X syndrome induced by deletions of CGG*CCG repeats.

Authors:  Robert D Wells
Journal:  J Biol Chem       Date:  2008-10-28       Impact factor: 5.157

3.  Familial transmission of the FMR1 CGG repeat.

Authors:  S L Nolin; F A Lewis; L L Ye; G E Houck; A E Glicksman; P Limprasert; S Y Li; N Zhong; A E Ashley; E Feingold; S L Sherman; W T Brown
Journal:  Am J Hum Genet       Date:  1996-12       Impact factor: 11.025

Review 4.  Novel opportunities for computational biology and sociology in drug discovery.

Authors:  Lixia Yao; James A Evans; Andrey Rzhetsky
Journal:  Trends Biotechnol       Date:  2010-04       Impact factor: 19.536

5.  Chromosomal fragility and human genetic disorders.

Authors:  S Baskaran; V Brahmachari
Journal:  Indian J Clin Biochem       Date:  2000-08

6.  Fragile X mental retardation protein regulates olfactory sensitivity but not odorant discrimination.

Authors:  Arielle Schilit Nitenson; Emily E Stackpole; Torrey L S Truszkowski; Maellie Midroit; Justin R Fallon; Kevin G Bath
Journal:  Chem Senses       Date:  2015-04-27       Impact factor: 3.160

7.  A multicenter study on genotype-phenotype correlations in the fragile X syndrome, using direct diagnosis with probe StB12.3: the first 2,253 cases.

Authors:  F Rousseau; D Heitz; J Tarleton; J MacPherson; H Malmgren; N Dahl; A Barnicoat; C Mathew; E Mornet; I Tejada
Journal:  Am J Hum Genet       Date:  1994-08       Impact factor: 11.025

Review 8.  Oxytocin and vasopressin systems in genetic syndromes and neurodevelopmental disorders.

Authors:  S M Francis; A Sagar; T Levin-Decanini; W Liu; C S Carter; S Jacob
Journal:  Brain Res       Date:  2014-01-22       Impact factor: 3.252

9.  Guidelines for the diagnosis of fragile X syndrome. National Fragile X Foundation.

Authors:  B A Oostra; P B Jacky; W T Brown; F Rousseau
Journal:  J Med Genet       Date:  1993-05       Impact factor: 6.318

10.  Array-based FMR1 sequencing and deletion analysis in patients with a fragile X syndrome-like phenotype.

Authors:  Stephen C Collins; Brad Coffee; Paul J Benke; Elizabeth Berry-Kravis; Fred Gilbert; Ben Oostra; Dicky Halley; Michael E Zwick; David J Cutler; Stephen T Warren
Journal:  PLoS One       Date:  2010-03-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.